Prostat Kanserinde Bakır, Berilyum, Bor, Titanyum ve Vanadyum İyonlarının Prognostik Önemi Var mı?

Amaç: Metal maruziyetin ile Prostatik adenokarsinom (PCa) ilişkilendiren birçok epidemiyolojik, klinik ve deneysel çalışma vardır. Bu çalışmada, benign prostat hiperplazisi (BPH) ile farklı histopatolojik grade de PCa ve bazı metal / ametal konsantrasyonları arasındaki ilişki araştırılmıştır.Materyal ve Metod: Bu çalışmaya 71 hasta dahil edildi. Hastaların parafin bloklarından alınan örnekler mikrodalga digestion işlemine tabi tutuldu ve örnekler İndüktif olarak eşleşmiş plazma kütle spektrometresi (ICP-MS) ile platin, talyum, kurşun, molibden, kadmiyum, selenyum77, selenium82, demir, potasyum, lityum, berilyum, bor, sodyum, magnezyum, fosfor, kalsiyum, titanyum, vanadyum, krom, manganez, kobalt, nikel, bakır, çinko, arsenik, stronsiyum, kalay ve antimony seviyeleri analiz edildi. Bulgular SPSS programı ile analiz edildi.Bulgular: BPH ve malign hasta gruplarında prostat dokusundaki metal / ametal düzeyler incelendiğinde istatitksel olarak lityum (p = 0,006), berilyum (p = 0,02), bor (p = 0,001), sodyum ( p = 0.009), magnezyum (p = 0.001), fosfor (p = 0.001), kalsiyum (p = 0.001), titanyum (p = 0.004), vanadyum (p = 0.001), krom (p = 0.04), manganez (p = 0,02), kobalt (p = 0,003), nikel (p = 0,005), bakır (p = 0,019), çinko (p = 0,001), arsenik (p = 0,002), stronsiyum (p = 0,001), kalay (p = 0.002) ve antimon (p = 0.001) bulundu. BPH dokularında berilyum, bor, titanyum ve vanadyum konsantrasyonları en az beş kat daha yüksekti. Gleason prognostik derece gruplamasına göre doku metal / ametal seviyeleri karşılaştırıldığında, doku bakır seviyeleri ile derece arasında anlamlı pozitif korelasyon bulundu (p = 0.02).Sonuç: Bu çalışma, berilyum, bor, titanyum ve vanadyumun iyi huylu prostat hiperplazisinde beş kat veya daha fazla olduğu gösterilmiştir. Ayrıca Bakır konsantrasyonunun artmasıyla histolojik derecenin yükseldiğini göstermiştir.Metal konsantrasyonları PCa da prognoz açısından dikkate alınmalıdır.

Is There A Prognostic Significance For Copper, Beryllium, Boron, Titanium and Vanadium Ions in Prostate Cancer?

Aim: There are several epidemiological, clinical and experimental studies that relate heavy metal exposure to Prostatic adenocarcinoma (PCa).In this study, the relationship between benign prostatic hyperplasia (BPH) and PCa, some metal/nonmetal concentrations at the level of the histopathological diagnosis was investigated.Materials and Methods: Seventy-one patients were included in this study.Thesamples taken from the paraffin blocks of the patients were subjected to microwave digestion, and the sampleswereanalyzedviaInductivelycoupledplasmamassspectrometry(ICP-MS)to determine the level oftissue concentrationsof platinum, thallium, lead,molybdenum, cadmium, selenium77, selenium82, iron, potassium, lithium, beryllium, boron, sodium, magnesium, phosphorus, calcium, titanium, vanadium, chromium, manganese, cobalt, nickel, copper, zinc, arsenic, strontium, tin, and antimony. The findings were analyzed with SPSS.Results: When metal/nonmetal levels in prostate tissue were examined in BPH and malignantpatientgroups,astatisticallysignificantdifferencewasfoundinthelevelsof lithium (p=0.006), beryllium (p=0.02), boron (p=0.001), sodium (p=0.009),magnesium (p=0.001), phosphorus (p=0.001), calcium (p=0.001), titanium (p=0.004), vanadium (p=0.001), chromium (p=0.04), manganese (p=0.02), cobalt (p=0.003), nickel (p=0.005), copper (p=0.019),zinc (p=0.001), arsenic (p=0.002),strontium (p=0.001), tin (p=0.002) and antimony (p=0.001). Beryllium, boron, titanium and vanadium concentrations were at least five times higher in BPH tissues.When tissue metal/nonmetal levels were compared according to the new Gleason prognostic grade grouping, a significant positive correlation was found between tissue copper levels and grade (p = 0.02).Conclusion: This study showed that beryllium, boron, titanium, and vanadium are five times or more in benign prostatic hyperplasia. It also showed that the histological grade increased with increasing copper concentration. Metal concentrations should be considered for prognosis in PCa.

PDF

___

Boffetta, P., Fryzek, J. P., & Mandel, J. S. (2012). Occupational exposure to beryllium and cancer risk: A review of the epidemiologic evidence. Critical Reviews in Toxicology, 42(2), 107–118. https://doi.org/10.3109/10408444.2011.631898
Bulka, C. M., Jones, R. M., Turyk, M. E., Stayner, L. T., & Argos, M. (2016). Arsenic in drinking water and prostate cancer in Illinois counties: An ecologic study. Environmental Research, 148, 450–456. https://doi.org/10.1016/j.envres.2016.04.030
Çelen, İ., Müezzino, T., Ataman, O. Y., & Bak, S. (2015). Selenium , nickel , and calcium levels in cancerous and non-cancerous prostate tissue samples and their relation with some parameters, Environmental Science and Pollution Research, 13070–13076. https://doi.org/10.1007/s11356-015-4555-y
Ck, V. Y. E. Z., Sviridova, T. v, & Zaichick, S. v. (1997). Zinc in the Human Prostate Gland: Normal, Hyperplastic and Cancerous, 29(5), 565–574.
Crawford, E. D. (2003). Epidemiology of prostate cancer chemoprevention. Urology, 62(Suppl 6A), 3–12. https://doi.org/10.1016/j.urology.2003.10.013 3
Crawford, E. D., Rosenberg, M. T., Partin, A. W., Cooperberg, M. R., Maccini, M., Loeb, S., Pettaway, C. A., Shore, N. D., Arangua, P., Hoenemeyer, J., Leveridge, M., Leapman, M., Pinto, P., Thompson, I. M., Carroll, P., Eastham, J., Gomella, L., & Klein, E. A. (2016). An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology, 96, 116–120. https://doi.org/10.1016/J.UROLOGY.2016.07.001
Cui, Y., Winton, M. I., Zhang, Z. F., Rainey, C., Marshall, J., de Kernion, J. B., & Eckhert, C. D. (2004). Dietary boron intake and prostate cancer risk. Oncology Reports, 11(4), 887–892.
Falkeholm, L., Grant, C. A., Magnusson, A., & Möller, E. (2001). Xylene-free method for histological preparation: A multicentre evaluation. Laboratory Investigation, 81(9), 1213–1221. https://doi.org/10.1038/labinvest.3780335
Genchi, G., Sinicropi, M. S., Lauria, G., Carocci, A., & Catalano, A. (2020, June 1). The effects of cadmium toxicity. International Journal of Environmental Research and Public Health, https://doi.org/10.3390/ijerph17113782
Gumulec, J., Masarik, M., Adam, V., Eckschlager, T., Provaznik, I., & Kizek, R. (2014). Serum and tissue zinc in epithelial malignancies: A meta-analysis. Plos one, e99790 9(6). https://doi.org/10.1371/journal.pone.0099790
Jin, J., Li, Z., Liu, J., Wu, Y., Gao, X., & He, Y. (2015). Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression. Oncology Reports, 34(3), 1431– 1439. https://doi.org/10.3892/or.2015.4097
Leitzmann, M. F., Stampfer, M. J., Wu, K., Colditz, G. A., Willett, W. C., & Giovannucci, E. L. (2003). Zinc supplement use and risk of prostate cancer. Journal of the National Cancer Institute, 95(13), 1004–1007. https://doi.org/10.1093/jnci/95.13.1004
Li, X. M., Zhang, L., Li, J., Li, Y., Wang, H. L., Ji, G. Y., Kuwahara, M., & Zhao, X. J. (2005). Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL. Asian Journal of Andrology, 7(3), 323– 328. https://doi.org/10.1111/j.1745-7262.2005.00044.x
Lim, J. T., Tan, Y. Q., Valeri, L., Lee, J., Geok, P. P., Chia, S. E., Ong, C. N., & Seow, W. J. (2019). Association between serum heavy metals and prostate cancer risk– A multiple metal analysis. Environment International, 132:105109 https://doi.org/10.1016/j.envint.2019.105109
Navarro Silvera, S. a, & Rohan, T. E. (2007). Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control, 18(1), 7–27. https://doi.org/10.1007/s10552-006-0057-z
Neslund-dudas, C. (2015). Biological Trace Element Research,157(2),107–112. https://doi.org/10.1007/s12011-013-9874-6.Prostate
Orenay Boyacioglu, S., Korkmaz, M., Kahraman, E., Yildirim, H., Bora, S., & Ataman, O. Y. (2017). Biological effects of tolerable level chronic boron intake on transcription factors. Journal of Trace Elements in Medicine and Biology, 39, 30–35. https://doi.org/10.1016/j.jtemb.2016.06.009
Rebbeck, T. R. (2006). Conquering cancer disparities: New opportunities for cancer epidemiology, biomarker, and prevention research. Cancer Epidemiology Biomarkers and Prevention, 15(9), 1569–1571. https://doi.org/10.1158/1055-9965.EPI-06-0613
Rock, C. L., Thomson, C., Gansler, T., Gapstur, S. M., McCullough, M. L., Patel, A. v., Andrews, K. S., Bandera, E. v., Spees, C. K., Robien, K., Hartman, S., Sullivan, K., Grant, B. L., Hamilton, K. K., Kushi, L. H., Caan, B. J., Kibbe, D., Black, J. D., Wiedt, T. L., McMahon, C., Sloan, K., & Doyle, C. (2020). American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer Journal for Clinicians, 70(4), 245–271. https://doi.org/10.3322/caac.21591
Rooney, C., Beral, V., Maconochie, N., Fraser, P., & Davies, G. (1993). Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority. BMJ (Clinical Research Ed.), 307(6916), 1391–1397. https://doi.org/10.1136/bmj.307.6916.1391
Sanderson, W. T., Ward, E. M., Steenland, K., & Petersen, M. R. (2001). Lung cancer case-control study of beryllium workers. American Journal of Industrial Medicine, 39(2), 133–144. https://doi.org/10.1002/1097- 0274(200102)39:2<133::AID-AJIM1001>3.0.CO;2-7
Sarafanov, A. G., Todorov, T. I., Centeno, J. a, Macias, V., Gao, W., Liang, W.-M., Beam, C., Gray, M. a, & Kajdacsy-Balla, A. a. (2011). Prostate cancer outcome and tissue levels of metal ions. The Prostate, 71(11), 1231–1238. https://doi.org/10.1002/pros.21339
Singh, B. P., Dwivedi, S., Dhakad, U., Murthy, R. C., Choubey, V. K., Goel, A., & Sankhwar, S. N. (2016). Status and Interrelationship of Zinc, Copper, Iron, Calcium and Selenium in Prostate Cancer. Indian Journal of Clinical Biochemistry, 31(1), 50–56. https://doi.org/10.1007/s12291-015-0497-x
Spitz, M. R., Strom, S. S., Yamamura, Y., Troncoso, P., Babaian, R. J., Scardino, P. T., Wheeler, T., Amos, C. I., von Eschenbach, A., & Kagan, J. (2000). Epidemiologic determinants of clinically relevant prostate cancer. International Journal of Cancer, 89(3), 259–264. https://doi.org/10.1002/1097- 0215(20000520)89:3<259::AID-IJC8>3.0.CO;2-F
Takatani-Nakase, T. (2018). Zinc Transporters and the Progression of Breast Cancers. Biological and Pharmaceutical Bulletin, 41(10), 1517-1522.
To, P. K., Do, M. H., Cho, J. H., & Jung, C. (2020). Growth modulatory role of zinc in prostate cancer and application to cancer therapeutics. International Journal of Molecular Sciences, 21(8). https://doi.org/10.3390/ijms21082991
Vinay Kumar, Abul Abbas, J. A. (2014). Robbins Basic Pathology (9th Editio). Philadelphia: Elsevier Inc.
Visuri, T., Pukkala, E., Pulkkinen, P., & Paavolainen, P. (2003). Decreased cancer risk in patients who have been operated on with total hip and knee arthroplasty for primary osteoarthrosis: a meta-analysis of 6 Nordic cohorts with 73,000 patients. Acta Orthopaedica Scandinavica, 74(3), 351–360. https://doi.org/10.1080/00016470310014300
Visuri, T., Pulkkinen, P., Paavolainen, P., & Pukkala, E. (2010). Cancer risk is not increased after conventional hip arthroplasty. Acta Orthopaedica, 81(1), 77–81. https://doi.org/10.3109/17453671003667150
Yaman, M., Atici, D., Bakirdere, S., & Akdeniz, I. (2005). Comparison of trace metal concentrations in malign and benign human prostate. Journal of Medicinal Chemistry, 48(2), 630–634. https://doi.org/10.1021/jm0494568
Zaichick, V., Nosenko, S., & Moskvina, I. (2012). The effect of age on 12 chemical element contents in the intact prostate of adult men investigated by inductively coupled plasma atomic emission spectrometry. Biological Trace Element Research, 147(1–3), 49–58. https://doi.org/10.1007/s12011-011-9294-